Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 3
2011 1
2012 2
2013 7
2014 10
2015 8
2016 5
2017 9
2018 16
2019 16
2020 16
2021 26
2022 25
2023 35
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF; HEART-FID Investigators. Mentz RJ, et al. N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26. N Engl J Med. 2023. PMID: 37632463 Clinical Trial.
BACKGROUND: Ferric carboxymaltose therapy reduces symptoms and improves quality of life in patients who have heart failure with a reduced ejection fraction and iron deficiency. Additional evidence about the effects of ferric
BACKGROUND: Ferric carboxymaltose therapy reduces symptoms and improves quality of life in patients who have heart
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Ponikowski P, et al. Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31. Eur Heart J. 2015. PMID: 25176939 Free PMC article. Clinical Trial.
AIM: The aim of this study was to evaluate the benefits and safety of long-term i.v. iron therapy in iron-deficient patients with heart failure (HF). ...Patients were randomized 1 : 1 to treatment with i.v. iron, as ferric
AIM: The aim of this study was to evaluate the benefits and safety of long-term i.v. iron therapy in iron-deficient patient
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Kalra PR, et al. Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Free article. Clinical Trial.
BACKGROUND: For patients with heart failure, reduced left ventricular ejection fraction and iron deficiency, intravenous ferric carboxymaltose administration improves quality of life and exercise capacity in the short-term and redu …
BACKGROUND: For patients with heart failure, reduced left ventricular ejection fraction and iron deficiency
Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Anker SD, et al. N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17. N Engl J Med. 2009. PMID: 19920054 Free article. Clinical Trial.
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left …
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous …
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA; AFFIRM-AHF investigators. Ponikowski P, et al. Lancet. 2020 Dec 12;396(10266):1895-1904. doi: 10.1016/S0140-6736(20)32339-4. Epub 2020 Nov 13. Lancet. 2020. PMID: 33197395 Clinical Trial.
BACKGROUND: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. ...INTERPRETATION: In patients with iron deficiency
BACKGROUND: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with c …
Iron deficiency in heart failure.
Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Loncar G, et al. ESC Heart Fail. 2021 Aug;8(4):2368-2379. doi: 10.1002/ehf2.13265. Epub 2021 May 1. ESC Heart Fail. 2021. PMID: 33932115 Free PMC article. Review.
Iron deficiency is a major heart failure co-morbidity present in about 50% of patients with stable heart failure irrespective of the left ventricular function. ...Beneficial effect of iron deficiency treatment on morb
Iron deficiency is a major heart failure co-morbidity present in about 50% of patients with stable hea
Highlights in heart failure.
Tomasoni D, Adamo M, Lombardi CM, Metra M. Tomasoni D, et al. ESC Heart Fail. 2019 Dec;6(6):1105-1127. doi: 10.1002/ehf2.12555. ESC Heart Fail. 2019. PMID: 31997538 Free PMC article. Review.
Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. ...Potassium lowering agents may allow initiation and titration of mineralocorticoid antagonists in a larger proportion of patients. Meta-analyses suggest better outco
Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. ...Potassium lowering agents may a
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A; EFFECT-HF Investigators. van Veldhuisen DJ, et al. Circulation. 2017 Oct 10;136(15):1374-1383. doi: 10.1161/CIRCULATIONAHA.117.027497. Epub 2017 Jul 12. Circulation. 2017. PMID: 28701470 Free PMC article. Clinical Trial.
BACKGROUND: Iron deficiency is common in patients with heart failure (HF) and is associated with reduced exercise capacity and poor outcomes. Whether correction of iron deficiency with (intravenous) ferric carboxymaltose
BACKGROUND: Iron deficiency is common in patients with heart failure (HF) and is associated with reduced …
Iron Deficiency in Heart Failure: An Overview.
von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. von Haehling S, et al. JACC Heart Fail. 2019 Jan;7(1):36-46. doi: 10.1016/j.jchf.2018.07.015. Epub 2018 Dec 12. JACC Heart Fail. 2019. PMID: 30553903 Free article. Review.
Iron deficiency is an extremely common comorbidity in patients with heart failure, affecting up to 50% of all ambulatory patients. ...This paper highlights current knowledge of the pathophysiology of iron deficiency in he
Iron deficiency is an extremely common comorbidity in patients with heart failure, affecting up to 50% of
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF; HEART-FID Trial Investigators. Mentz RJ, et al. Circ Heart Fail. 2021 May;14(5):e008100. doi: 10.1161/CIRCHEARTFAILURE.120.008100. Epub 2021 May 18. Circ Heart Fail. 2021. PMID: 34003690 Free PMC article.
BACKGROUND: Iron deficiency (ID) has a prevalence of 40% to 50% among patients in heart failure (HF) with reduced ejection fraction and is associated with worse prognosis. ...METHODS: The objective of the HEART-FID trial (Ferric
BACKGROUND: Iron deficiency (ID) has a prevalence of 40% to 50% among patients in heart failure (HF) with …
167 results